GamaMabs Pharma SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GamaMabs Pharma SA
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Murlentamab Phase II results indicate its potential for use in combination with chemotherapy or other immunological agents, to target AMHRII-expressing tumors.
This Month's Profile Group, Antibodies Evolve, features profiles of GamaMabs, Numab, and Zebra Biologics. Plus these Start-Ups Across Health Care: CoolCore Biomedical Technologies, EBS Technologies, and Xeltis.
GamaMabs Pharma SA is one of the latest contenders aiming to boost the biological activity of antibodies by altering their attached sugar groups. The company, located in Toulouse, France, was founded in June 2013 to develop therapeutic antibody treatments for gynecologic cancers, using core technologies licensed from the French Laboratories for Biotechnologies.